发明授权
US07601732B2 Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin
失效
5（S） - （2'-羟基乙氧基）-20（S）-CAMPTOTHECIN的晶体形式
- 专利标题： Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin
- 专利标题（中）： 5（S） - （2'-羟基乙氧基）-20（S）-CAMPTOTHECIN的晶体形式
-
申请号： US11753392申请日： 2007-05-24
-
公开(公告)号： US07601732B2公开(公告)日： 2009-10-13
- 发明人: Venkateswarlu Akella , Shanavas Alikunju , Ajaya Kumar Reka , Ramesh Mullangi , Raju Sirisilla , Subrahmanyam Duvvuri , Sriram Rajagopal
- 申请人： Venkateswarlu Akella , Shanavas Alikunju , Ajaya Kumar Reka , Ramesh Mullangi , Raju Sirisilla , Subrahmanyam Duvvuri , Sriram Rajagopal
- 申请人地址： IN Hyderabad US NJ Bridgewater
- 专利权人： Dr. Reddy's Laboratories Limited,Dr. Reddy's Laboratories, Inc.
- 当前专利权人： Dr. Reddy's Laboratories Limited,Dr. Reddy's Laboratories, Inc.
- 当前专利权人地址： IN Hyderabad US NJ Bridgewater
- 代理机构： Nelson Mullins Riley & Scarborough, LLP
- 优先权： IN897/CHE/2006 20060524
- 主分类号： A61K31/4745
- IPC分类号： A61K31/4745 ; C07D491/22
摘要：
A crystalline form of 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2θ that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.
公开/授权文献
信息查询
IPC分类:
